Lead drug candidate NPT001 for Alzheimer’s

• Biochemistry and biophysical mechanism proven
• Strong efficacy in transgenic mice models of AD
• Manufacturing process in scale-up
• Initial meeting held with FDA
• First-in-human study planned to include both safety and activity endpoints